Recombinant Human OVOL3 protein

OVOL3 (Ovo-Like Transcriptional Repressor 3) is a member of the OVOL family of transcription factors, which are evolutionarily conserved regulators of cellular differentiation and development. The OVOL family, including OVOL1. OVOL2. and OVOL3. plays critical roles in epithelial cell fate determination, epithelial-mesenchymal transition (EMT), and tissue morphogenesis. OVOL3. specifically, is less characterized compared to OVOL1 and OVOL2 but shares structural features such as a conserved zinc-finger DNA-binding domain, enabling sequence-specific interactions with target gene promoters. It functions primarily as a transcriptional repressor, modulating genes involved in cell cycle progression, differentiation, and EMT.

Research suggests OVOL3 is implicated in maintaining epithelial cell identity by suppressing mesenchymal traits, thereby influencing tissue homeostasis and repair. Its expression is detected in various epithelial tissues, including the skin, gut, and reproductive organs. Dysregulation of OVOL3 has been linked to pathological conditions, particularly cancers, where it may act as a tumor suppressor by inhibiting pro-metastatic pathways. For instance, reduced OVOL3 expression correlates with increased invasiveness in certain carcinomas, highlighting its role in restraining EMT-driven metastasis.

Recombinant OVOL3 protein is engineered for in vitro and in vivo studies to elucidate its molecular mechanisms. Produced typically in bacterial or mammalian expression systems, the recombinant protein retains functional domains necessary for DNA binding and transcriptional regulation. It is utilized in assays such as electrophoretic mobility shift assays (EMSAs), chromatin immunoprecipitation (ChIP), and cell-based reporter systems to identify target genes and signaling pathways. Additionally, it aids in structural studies to map interaction interfaces with co-regulators or chromatin modifiers. As a tool, recombinant OVOL3 enables exploration of its therapeutic potential in cancer, fibrosis, and regenerative medicine, offering insights into strategies to manipulate epithelial plasticity for disease intervention.